Thomas E. Needham
Director/Board Member presso RENOVACOR, INC.
Profilo
Thomas E.
Needham is the founder of Synthesis Capital, which was founded in 2007.
He held the title of Principal at Synthesis Capital from 2007 to 2012.
Mr. Needham's current job(s) include being the Chairman at Renovacor Holdings, Inc. since 2020, Chairman at Basking Biosciences, Inc., Director at Broadview Ventures, Inc. since 2018, and Independent Director at Renovacor, Inc. since 2019.
Mr. Needham's former job(s) include being the President, Chief Executive Officer & Director at Spear Therapeutics Ltd., President & Director at Trident Pharmaceuticals, Inc., Director at Prexa Pharmaceuticals, Inc., Director at Kantum Pharma, Inc., Principal at Advent International LP from 2003 to 2007, Principal at ImmuLogic Pharmaceutical Corp., Vice President at GPC Biotech AG, Chief Business Officer at Merrimack Pharmaceuticals, Inc. from 2017 to 2018, Vice President at GPC Biotech, Inc., and Senior Vice President-Business Development at C4 Therapeutics, Inc. from 2016 to 2017.
Mr. Needham's education history includes an undergraduate degree from Bowdoin College in 1987 and an MBA from F.W.
Olin Graduate School of Business in 1992.
Posizioni attive di Thomas E. Needham
| Società | Posizione | Inizio |
|---|---|---|
| RENOVACOR, INC. | Director/Board Member | 01/08/2019 |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Chairman | 01/01/2020 |
Broadview Ventures, Inc.
 Broadview Ventures, Inc. Investment ManagersFinance Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/03/2018 |
Basking Biosciences, Inc.
 Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Chairman | - |
Precedenti posizioni note di Thomas E. Needham
| Società | Posizione | Fine |
|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2018 |
| C4 THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2017 |
Advent International LP
 Advent International LP Investment ManagersFinance Advent International LP (Advent) is an independent private equity firm founded in 1984 by Henry H. Haight. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/05/2007 |
GPC Biotech AG
 GPC Biotech AG Miscellaneous Commercial ServicesCommercial Services GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey | Corporate Officer/Principal | 01/05/2003 |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Corporate Officer/Principal | 01/05/2003 |
Formazione di Thomas E. Needham
| Bowdoin College | Undergraduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| Aziende private | 13 |
|---|---|
Advent International LP
Advent International LP Investment ManagersFinance Advent International LP (Advent) is an independent private equity firm founded in 1984 by Henry H. Haight. The firm is headquartered in Boston, Massachusetts. | Finance |
ImmuLogic Pharmaceutical Corp.
ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Health Technology |
Trident Pharmaceuticals, Inc.
 Trident Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trident Pharmaceuticals, Inc. develops novel biologics for the treatment of autoimmune disorders. The company was founded by Charles M. Cohen and Robin Brown in March 2006 and is headquartered in Boston, MA. | Health Technology |
Prexa Pharmaceuticals, Inc.
 Prexa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prexa Pharmaceuticals, Inc. developed oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It engaged in developing small molecules designed to enhance the action of the neurotransmitter dopamine, potentially providing new alternatives to treating CNS diseases and disorders such as ADHD, depression, and Parkinson's disease. The company was founded in 2006 and was headquartered in Boston, MA. | Health Technology |
GPC Biotech AG
GPC Biotech AG Miscellaneous Commercial ServicesCommercial Services GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey | Commercial Services |
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA. | Retail Trade |
Spear Therapeutics Ltd.
 Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Health Technology |
Broadview Ventures, Inc.
Broadview Ventures, Inc. Investment ManagersFinance Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts. | Finance |
Synthesis Capital
 Synthesis Capital Investment ManagersFinance Synthesis Capital is a venture capital firm founded in 2007. The firm is headquartered in Boston, Massachusetts. | Finance |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Health Technology |
Basking Biosciences, Inc.
Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Health Technology |
Renovacor, Inc.
 Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Thomas E. Needham
